The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study

and the Registration Committee of the Japanese HBOC consortium

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)

Abstract

Disease sites of female genital tract cancers of BRCA1/2-associated hereditary breast and ovarian cancer (HBOC) are less understood than non-hereditary cancers. We aimed to elucidate the disease site distribution of genital cancers in women with the germline BRCA1 and BRCA2 pathogenic variants (BRCA1+ and BRCA2+) of HBOC. For the primary disease site, the proportion of fallopian tube and peritoneal cancer was significantly higher in BRCA2+ (40.5%) compared with BRCA1+ (15.4%) and BRCA− (no pathogenic variant, 12.8%). For the metastatic site, the proportion of peritoneal dissemination was significantly higher in BRCA1+ (71.9%) than BRCA− (55.1%) and not different from BRCA2+ (71.4%). With one of the most extensive patients, this study supported the previous reports showing that the pathogenic variants of BRCA1/2 were involved in the female genitalia’s disease sites.

Original languageEnglish
Article number36
JournalWorld Journal of Surgical Oncology
Volume19
Issue number1
DOIs
Publication statusPublished - 12-2021

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study'. Together they form a unique fingerprint.

Cite this